Appl. No.

: 09/787,356

Filed

June 25, 2001

AMENDMENTS TO THE CLAIMS

- 1. (Currently amended) A method for a prophylaxis or a treatment of an airway disease condition in inflammation of an airway of an animal, said method comprising administering to said animal, an effective amount of an agent capable of activating an airway epithelium protease activated receptor-2 (PAR2) for a time and wherein under conditions sufficient for activation of said PAR2 to occur, the activated PAR2 stimulates, induces, or facilitates inhibition of bronchoconstriction and/or inflammation.
- 2. (Previously presented) The method according to Claim 1 wherein the animal is a human.
 - 3. (Canceled)
 - 4. (Canceled)
- 5. (Previously presented) The method according to Claim 1 wherein the airway disease condition is a disease selected from the group consisting of asthma, bronchitis, hayfever, alveolitis, ciliary dyskinesis and pulmonary inflammation.
- 6. (Currently amended) The method according to Claim 1 wherein the agent is a peptide selected from the group consisting of Seq.I.D. Nos. <400>1, <400>2, and <400>3 comprising the sequence of SEQ ID NO. 2 or SEQ ID NO:3 or functional equivalents, homologues, or derivatives thereof.
- 7. (Previously presented) The method according to Claim 6 wherein the peptide is modified to permit entry across an epithelial and/or subcutaneous layer.
- 8. (Previously presented) The method according to Claim 7 wherein the peptide is fused to penetratin.
- 9. (Previously presented) The method according to Claim 7 wherein the peptide is fused to TAT, a functional derivative or homologue thereof.

Claims 10-19 (Canceled)

20. (New) A method of identifying an agent for treatment or prophylaxis of inflammation of an airway of an animal, comprising determining whether the agent activates PAR2, wherein the agent can be used for said treatment if it does activate PAR2.

Appl. No. : 09/787,356 Filed : June 25, 2001

AMENDMENTS TO THE DRAWINGS

Enclosed please find the corrected figures with red ink markings designating the proposed changes to the drawings in this application for which approval by the Examiner is requested. The first Figure 38 (Panel 29/41) has been amended to recite "FIGURE 27." The first Figure 36 (Panel 37/41) has been amended to recite "FIGURE 35."